Roivant Sciences Ltd.
ROIV · XNASCIK 1635088fmd_1P50V243YFNEF4KE216NPHPFZCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Total revenues | 24 | 55 | 32 | 33 | 29 | 8 |
| Realized investment gains (losses) | 96 | (87) | (21) | (48) | 55 | 105 |
| Research and development | 237 | 483 | 454 | 440 | 550 | 682 |
| Selling, general and administrative | – | 775 | 601 | 687 | – | – |
| Total operating expenses | 1,095 | 1,407 | 938 | 884 | 1,143 | 1,294 |
| Operating income | (1,071) | (1,352) | (907) | 4,497 | (1,003) | (515) |
| Interest expense | 3 | 7 | 28 | 35 | – | – |
| Interest and investment income | – | – | – | 146 | 258 | 178 |
| Other non-operating income (expense) | (9) | 3 | (0) | (14) | (11) | 4 |
| Income before taxes | (899) | (924) | (885) | 4,568 | (682) | (265) |
| Income tax expense | 2 | 0 | 4 | 22 | 48 | 133 |
| Net income from continuing operations | (900) | (924) | (889) | 4,546 | (730) | (398) |
| Net income | (809) | (845) | (1,009) | 4,349 | (172) | (300) |
| Net income to common shareholders | – | – | – | 4,349 | (172) | (300) |